CA3247528A1 - SPLIT-SWITCHING ALLELE-SPECIFIC OLIGONUCLEOTIDES TARGETTING PSEUDOEXONS - Google Patents

SPLIT-SWITCHING ALLELE-SPECIFIC OLIGONUCLEOTIDES TARGETTING PSEUDOEXONS

Info

Publication number
CA3247528A1
CA3247528A1 CA3247528A CA3247528A CA3247528A1 CA 3247528 A1 CA3247528 A1 CA 3247528A1 CA 3247528 A CA3247528 A CA 3247528A CA 3247528 A CA3247528 A CA 3247528A CA 3247528 A1 CA3247528 A1 CA 3247528A1
Authority
CA
Canada
Prior art keywords
sso
pseudoexon
splice site
disease
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3247528A
Other languages
English (en)
French (fr)
Inventor
Brage Storstein ANDRESEN
Thomas Koed DOKTOR
Lise Lolle HOLM
Ulrika Simone Spangsberg PETERSEN
Gitte Hoffmann BRUUN
Original Assignee
Syddansk Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2022/051790 external-priority patent/WO2022162020A2/en
Application filed by Syddansk Universitet filed Critical Syddansk Universitet
Publication of CA3247528A1 publication Critical patent/CA3247528A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3247528A 2022-01-26 2023-01-26 SPLIT-SWITCHING ALLELE-SPECIFIC OLIGONUCLEOTIDES TARGETTING PSEUDOEXONS Pending CA3247528A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2022/051790 2022-01-26
PCT/EP2022/051790 WO2022162020A2 (en) 2021-01-26 2022-01-26 Splice switching oligonucleotides targeting pseudoexons
DKPA202270346 2022-06-29
DKPA202270346 2022-06-29
PCT/EP2023/051916 WO2023144263A1 (en) 2022-01-26 2023-01-26 Allele specific splice switching oligonucleotides targeting pseudoexons

Publications (1)

Publication Number Publication Date
CA3247528A1 true CA3247528A1 (en) 2023-08-03

Family

ID=85108839

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3247528A Pending CA3247528A1 (en) 2022-01-26 2023-01-26 SPLIT-SWITCHING ALLELE-SPECIFIC OLIGONUCLEOTIDES TARGETTING PSEUDOEXONS

Country Status (7)

Country Link
US (1) US20250101419A1 (https=)
EP (1) EP4469572A1 (https=)
JP (1) JP2025504661A (https=)
CN (1) CN119013399A (https=)
AU (1) AU2023210747A1 (https=)
CA (1) CA3247528A1 (https=)
WO (1) WO2023144263A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024243087A2 (en) * 2023-05-19 2024-11-28 Leverna Therapeutics Inc. Compositions and methods for regulating expression of atxn2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108603230A (zh) * 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
WO2017087282A1 (en) * 2015-11-18 2017-05-26 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting leucine-rich repeat kinase 2 (lrrk2) for the treatment of parkinsons disease
KR102318434B1 (ko) * 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
TWI833770B (zh) * 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法
US12595479B2 (en) * 2019-03-20 2026-04-07 President And Fellows Of Harvard College Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
WO2022119881A1 (en) * 2020-12-01 2022-06-09 Emendobio Inc. Differential knockout of a heterozygous allele of lrrk2
CA3204779A1 (en) * 2021-01-26 2022-08-04 Brage Storstein Andresen Splice switching oligonucleotides targeting pseudoexons

Also Published As

Publication number Publication date
WO2023144263A1 (en) 2023-08-03
AU2023210747A1 (en) 2024-08-01
CN119013399A (zh) 2024-11-22
EP4469572A1 (en) 2024-12-04
JP2025504661A (ja) 2025-02-14
US20250101419A1 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
US20240033378A1 (en) Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
Chen et al. Concentration-dependent control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins
US9803195B2 (en) Natural antisense and non-coding RNA transcripts as drug targets
Webster et al. Maturation of small nucleolar RNAs: from production to function
JP5982362B2 (ja) Ｐａｒ４への天然アンチセンス転写物の阻害によるｐａｒ４関連疾患の治療
TWI901675B (zh) 用於病症及疾病之治療的opa1反義寡聚物
EP3201339A2 (en) Targeted augmentation of nuclear gene output
JP2016185148A (ja) Ａｔｏｈ１に対する天然アンチセンス転写物の阻害による無調ホモログ１（ａｔｏｈ１）関連疾患の治療
US11866784B2 (en) Exonic splicing enhancers and exonic splicing silencers
TW201201819A (en) Treatment of BCL2-like 11 (BCL2L11) related diseases by inhibition of natural antisense transcript to BCL2L11
Saramago et al. The implication of mRNA degradation disorders on human DISease: focus on DIS3 and DIS3-like enzymes
TW201209163A (en) Treatment of BCL2 binding component 3 (BBC3) related diseases by inhibition of natural antisense transcript to BBC3
Chen et al. Tumor-associated intronic editing of HNRPLL generates a novel splicing variant linked to cell proliferation
US10266828B2 (en) RAS exon 2 skipping for cancer treatment
Xie et al. Inhibition of microRNA-30a prevents puromycin aminonucleoside-induced podocytic apoptosis by upregulating the glucocorticoid receptor α
US20250101419A1 (en) Allele specific splice switching oligonucleotides targeting pseudoexons
CA3204779A1 (en) Splice switching oligonucleotides targeting pseudoexons
WO2023049800A1 (en) Therapeutics for haploinsufficiency conditions
US20250277214A1 (en) Splice switching oligonucleotides targeting pseudoexons
US20240117353A1 (en) Compositions for treatment of conditions and diseases associated with polycystin expression
WO2013017542A1 (en) Method for preventing or treating memory impairment and pharmaceutical compositions useful therefor
US20260035694A1 (en) Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
US20230167447A1 (en) Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof
Chen et al. The long noncoding RNA LINC00200 promotes the malignant progression of MYCN-amplified neuroblastoma via binding to insulin like growth factor 2 mRNA binding protein 3 (IGF2BP3) to enhance the stability of Zic family member 2 (ZIC2) mRNA
US20220348916A1 (en) Composition for diagnosis or treatment of a condition associated with increased activity of eif4e comprising an eif4e inhibitor

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240708

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241216

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241216

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241216

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250113

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250113

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250113

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250207

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250207

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260120